
UB388
TargetsAR
IndicationsMetastatic castration-resistant prostate cancer; Prostate cancer
ClinicalCN - I
TherapeuticsOncology
ModalitiesSmall Molecule
Exclusive Summary
- • A Potential Best-in-class AR degrader.
- • Capable of degrading AR gene amplification and drug-resistant mutations in the AR-LBD domain, including the L702H mutation.
- • In vitro and in vivo activity is significantly superior to that of ARV766.
我们能如何帮助您?
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →